CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis

PURPOSE: ER+/HER2- advanced breast cancer (ABC) with visceral crisis (VC) or impending VC (IVC) is commonly treated with chemotherapy instead of CDK4/6 inhibitors (CDK4/6i). However, there is little evidence to confirm which treatment is superior. This study compared outcomes of patients with ER+/HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Behrouzi, Roya, Armstrong, Anne C., Howell, Sacha J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504109/
https://www.ncbi.nlm.nih.gov/pubmed/37584881
http://dx.doi.org/10.1007/s10549-023-07035-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504109/
https://www.ncbi.nlm.nih.gov/pubmed/37584881
http://dx.doi.org/10.1007/s10549-023-07035-6

Ejemplares similares